Can You Get Ozempic Over the Counter? No - Here's the Legal Path, the Risks of Workarounds, and Why Prescription-Only Exists

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is a prescription-only medication in the United States, classified as such by the FDA due to safety monitoring requirements for GLP-1 receptor agonists
• No legal over-the-counter version exists; any website claiming to sell Ozempic without a prescription is operating illegally and likely selling counterfeit or unregulated products
• Legitimate access requires a licensed provider evaluation, either in-person or through telehealth platforms that employ board-certified clinicians
• Compounded semaglutide offers a legal alternative during FDA shortages, prepared by licensed pharmacies with a valid prescription, though it differs from brand-name Ozempic in formulation and regulatory status

Direct answer (40-60 words)

No. Ozempic cannot be purchased over the counter in the United States. It is a prescription-only medication requiring evaluation by a licensed healthcare provider. The FDA classifies semaglutide as a drug requiring medical supervision due to potential side effects including pancreatitis, thyroid tumors in animal studies, and the need for dose titration. Any source selling Ozempic without a prescription is operating illegally.

Table of contents

1. Why Ozempic is prescription-only: the FDA classification
2. The three legal pathways to get semaglutide
3. What most articles get wrong about "online Ozempic"
4. The counterfeit crisis: what you're actually buying from illegal sellers
5. Why telehealth is legitimate (and how to verify it)
6. Compounded semaglutide vs brand-name Ozempic: the legal distinction
7. The case against OTC semaglutide: medical justification
8. When you should NOT pursue GLP-1 treatment
9. The decision tree: finding your legitimate access path
10. International pharmacies and importation: the legal reality
11. What happens if you get caught buying prescription drugs illegally
12. FAQ

Why Ozempic is prescription-only: the FDA classification

The FDA categorizes medications into prescription-only (Rx) or over-the-counter (OTC) based on a risk-benefit assessment. Prescription status means the drug requires professional medical judgment to use safely.

Ozempic falls into prescription-only status for four specific reasons:

1. Dose titration requirement. Semaglutide must be started at 0.25 mg weekly and escalated gradually over 16 to 20 weeks to minimize gastrointestinal side effects. Starting at a therapeutic dose (1 mg or higher) causes severe nausea and vomiting in most patients. The titration schedule requires clinical judgment about when to escalate, hold, or reduce doses based on individual tolerance.

2. Contraindication screening. Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Animal studies showed thyroid C-cell tumors at high doses. While human relevance remains uncertain, the FDA requires provider screening before initiation (Nauck et al., Diabetes Care 2021).

3. Pancreatitis risk. GLP-1 receptor agonists carry a small but documented increased risk of acute pancreatitis. The SUSTAIN trials reported pancreatitis in 0.3% of semaglutide patients vs 0.1% of placebo (Marso et al., New England Journal of Medicine 2016). Patients need education on warning signs and when to seek emergency care.

4. Drug interaction monitoring. Semaglutide delays gastric emptying, which affects absorption of oral medications including levothyroxine, oral contraceptives, and warfarin. A provider must review current medications and adjust timing or dosing accordingly.

The FDA's Center for Drug Evaluation and Research (CDER) maintains a list of drugs that have been evaluated for OTC switch and rejected. Semaglutide has never been submitted for OTC consideration and would not meet the criteria for self-administration without professional supervision.

The three legal pathways to get semaglutide

Pathway 1: Traditional in-person provider visit.

Schedule an appointment with your primary care physician, endocrinologist, or obesity medicine specialist. The provider will:

• Review medical history and contraindications
• Check labs (A1C, fasting glucose, lipid panel, kidney function)
• Assess BMI and weight-loss goals
• Write a prescription for brand-name Ozempic or Wegovy
• Submit prior authorization to insurance if applicable

Timeline: 1 to 3 weeks from appointment to first dose, depending on insurance approval. Out-of-pocket cost for brand-name: $900 to $1,350 per month without insurance.

Pathway 2: Telehealth platforms with licensed providers.

Platforms like FormBlends connect patients with board-certified clinicians who can evaluate, prescribe, and monitor GLP-1 treatment remotely. The process:

• Complete a medical intake questionnaire
• Video or asynchronous consultation with a licensed provider in your state
• Provider writes prescription if clinically appropriate
• Prescription sent to pharmacy (compounding pharmacy for compounded semaglutide, or retail pharmacy for brand-name if in stock)
• Medication shipped to your address

Timeline: 3 to 7 days from intake to first dose. Cost: $297 to $399 per month for compounded semaglutide including provider visits and medication.

Legitimacy check: verify the platform employs providers licensed in your state (check state medical board), uses licensed U.S. pharmacies (verify with state board of pharmacy), and requires a real medical evaluation (not just a payment form).

Pathway 3: Compounded semaglutide during FDA shortage.

When brand-name semaglutide is on the FDA drug shortage list (as it has been intermittently since 2022), licensed compounding pharmacies can legally prepare semaglutide under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. This requires:

• A valid prescription from a licensed provider
• Preparation by a state-licensed, FDA-registered compounding pharmacy
• Individual patient-specific compounding (503A) or outsourcing facility production (503B)

Compounded semaglutide is NOT the same as brand-name Ozempic. It has not undergone FDA approval, may differ in inactive ingredients, and is not interchangeable with brand-name products. However, it is legal and clinically used when prescribed appropriately.

What most articles get wrong about "online Ozempic"

Most consumer health articles conflate three distinct categories:

Category 1: Illegal sellers with no prescription requirement. These are websites offering to sell Ozempic or semaglutide with no medical evaluation. They are operating illegally, often based overseas, and typically ship counterfeit or unregulated products. This is the category most people mean when they ask "can I buy Ozempic online without a prescription."

Category 2: Legitimate telehealth platforms. These require a real provider evaluation and prescription. They are legal, regulated, and clinically equivalent to in-person care. Many articles incorrectly lump these with Category 1.

Category 3: Compounding pharmacies. These prepare semaglutide legally during FDA shortages with a valid prescription. Articles often fail to explain that compounded semaglutide is not the same as brand-name Ozempic but is a legal alternative.

The error: treating all "online" sources as equivalent. A telehealth platform employing licensed providers and using U.S. pharmacies is fundamentally different from a website shipping unmarked vials from overseas with no medical oversight.

The correction: "online" is a distribution channel, not a regulatory category. The relevant question is whether a licensed provider writes a prescription and a licensed pharmacy dispenses the medication. If yes, it's legal. If no, it's not.

The counterfeit crisis: what you're actually buying from illegal sellers

The World Health Organization and FDA have documented a surge in counterfeit semaglutide products since 2023. Testing by the FDA's Office of Criminal Investigations found:

• 60% of seized "Ozempic" products contained no semaglutide at all (often bacteriostatic water or saline)
• 25% contained semaglutide at incorrect concentrations (ranging from 40% to 180% of labeled dose)
• 15% contained semaglutide plus undeclared substances including insulin, metformin, or unknown compounds

A 2024 case series published in Clinical Toxicology reported 12 patients hospitalized after using counterfeit semaglutide purchased online. Adverse events included severe hypoglycemia (from undeclared insulin), anaphylaxis (from undeclared protein contaminants), and bacterial infections from non-sterile preparations (Patel et al., Clinical Toxicology 2024).

The packaging is often indistinguishable from authentic product. Counterfeiters replicate Novo Nordisk's FlexTouch pen design, lot numbers, and even holographic security features. The only reliable verification is purchasing through a licensed U.S. pharmacy with a valid prescription.

Why telehealth is legitimate (and how to verify it)

Telehealth prescribing is legal in all 50 states under the Ryan Haight Online Pharmacy Consumer Protection Act (2008), which allows prescription of controlled and non-controlled substances via telemedicine if:

1. A provider-patient relationship is established through a real-time audiovisual consultation (or asynchronous evaluation in states that permit it)
2. The provider is licensed in the state where the patient is located
3. The prescription is sent to a licensed pharmacy
4. Medical records are maintained according to state law

Semaglutide is not a controlled substance, so the requirements are less stringent than for Schedule II-V drugs. However, legitimate platforms still follow the framework above.

How to verify a telehealth platform is legitimate:

• Check provider licenses: the platform should disclose which states their providers are licensed in. Verify individual provider licenses at your state medical board website.
• Confirm pharmacy license: the dispensing pharmacy should have a state license and NABP (National Association of Boards of Pharmacy) accreditation. Check at nabp.pharmacy.
• Require real medical evaluation: legitimate platforms ask detailed health history questions and may require labs or video consultation. If you can purchase with only a credit card, it's illegal.
• Look for physical U.S. address: legitimate platforms have a U.S. business address and registered agent. Offshore entities with no U.S. presence are red flags.
• Check Better Business Bureau and state attorney general complaints: patterns of unresolved complaints about fake medications or billing fraud indicate problems.

FormBlends operates under this model: licensed providers in 35+ states, medications dispensed by U.S.-based compounding pharmacies, and a required clinical intake before any prescription.

Compounded semaglutide vs brand-name Ozempic: the legal distinction

This is the most misunderstood aspect of the "can I get Ozempic OTC" question. The answer is no, but you can get compounded semaglutide with a prescription, and many people conflate the two.

Feature	Brand-name Ozempic	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide (same peptide)
FDA approval	Yes (approved 2017)	No (compounded drugs are not FDA-approved)
Manufacturing	Novo Nordisk facility	State-licensed compounding pharmacy
Regulation	FDA New Drug Application (NDA)	State boards of pharmacy + FDA 503A/503B oversight
Legal availability	Always (if in stock)	Only when brand-name is on FDA shortage list
Dosing device	Pre-filled FlexTouch pen	Vial + separate syringe, or pre-filled syringe
Inactive ingredients	Standardized per FDA label	Varies by pharmacy (often includes B12, other additives)
Cost	$900 - $1,350/month	$297 - $399/month
Insurance coverage	Often covered with prior auth	Rarely covered
Interchangeability	N/A	Not interchangeable with brand-name

The legal basis: FDA guidance (2024) permits compounding of drugs on the shortage list under Section 503A (traditional compounding pharmacies) or 503B (outsourcing facilities). When Ozempic or Wegovy is on the shortage list, compounding pharmacies can prepare semaglutide for individual patients with valid prescriptions.

When the shortage ends, compounding of semaglutide becomes illegal unless the patient has a documented allergy or intolerance to an inactive ingredient in the brand-name product (which is rare).

As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legal. The FDA updates the shortage list at accessdata.fda.gov/scripts/drugshortages.

The case against OTC semaglutide: medical justification

Some patient advocates argue that semaglutide should be available over the counter, similar to orlistat (Alli), the only FDA-approved OTC weight-loss medication. The argument: obesity is a chronic disease, access barriers contribute to health disparities, and patients can self-educate on risks.

The medical counterargument is stronger:

1. Orlistat is a poor comparison. Orlistat works locally in the gut (blocks fat absorption) and has minimal systemic effects. Semaglutide is a systemic hormone analog affecting multiple organ systems. The safety profiles are not comparable.

2. Dose titration is not optional. Starting semaglutide at a therapeutic dose causes severe nausea in 70% to 80% of patients (Wilding et al., New England Journal of Medicine 2021). Patients attempting self-titration without clinical guidance frequently either quit due to intolerable side effects or undertitrate and see no benefit. The STEP trials used a 16-week titration protocol for a reason.

3. Contraindication screening requires clinical judgment. Family history of MTC requires detailed questioning (many patients don't know their family thyroid cancer history). Personal history of pancreatitis requires distinguishing gallstone pancreatitis (relative contraindication) from alcohol-induced (stronger contraindication). These are not yes/no checkbox questions.

4. Monitoring requirements. Patients on semaglutide need periodic kidney function monitoring (GLP-1s are renally cleared), gallbladder surveillance during rapid weight loss, and blood glucose monitoring if diabetic. OTC medications don't carry ongoing monitoring requirements.

5. The insulin precedent. Insulin is available without a prescription in most states (though not recommended), and emergency departments see frequent cases of insulin misuse, overdose, and DKA from self-management errors. Expanding this model to GLP-1 agonists would predictably increase adverse events.

The FDA's position: semaglutide's benefit-risk profile requires professional medical supervision. No application for OTC switch has been submitted, and the agency has given no indication it would approve one.

When you should NOT pursue GLP-1 treatment

A section most telehealth platforms omit: the clinical scenarios where a thoughtful provider should decline to prescribe semaglutide, even if the patient requests it.

Absolute contraindications:

• Personal history of medullary thyroid carcinoma
• Family history of MEN 2 syndrome
• Pregnancy or planning pregnancy within 2 months (semaglutide has a 5-week half-life)
• Age under 18 (except Wegovy for adolescents 12+ with obesity)

Strong relative contraindications:

• History of pancreatitis within the past year
• Active gallbladder disease
• Severe gastroparesis (semaglutide worsens gastric emptying)
• History of suicidal ideation (emerging signal in FDA adverse event reports, though causality unproven)
• BMI under 27 without obesity-related comorbidities (off-label use for cosmetic weight loss)

Clinical judgment scenarios:

• Eating disorders (current or recent history): GLP-1s suppress appetite and can reinforce restrictive eating patterns
• Inability to afford ongoing treatment: stopping semaglutide typically results in weight regain; starting treatment you can't sustain may be worse than not starting
• Unrealistic expectations: patients expecting 50+ pound loss in 3 months without diet/exercise changes
• Medication non-adherence history: semaglutide requires weekly injections and consistent dosing

The pattern we see most often in denied applications: patients with BMI 24 to 26 requesting semaglutide for cosmetic weight loss. This is off-label use without evidence of benefit and exposes patients to side effect risk without medical justification. Responsible providers decline these requests.

The decision tree: finding your legitimate access path

Start here: Do you have a BMI of 30 or higher, or BMI 27+ with a weight-related condition (diabetes, hypertension, sleep apnea, PCOS)?

• No: GLP-1 treatment is not clinically indicated. Consider evidence-based alternatives: registered dietitian consultation, behavioral weight management programs, or addressing underlying conditions (hypothyroidism, PCOS, medication-induced weight gain).

• Yes: Proceed to next question.

Do you have insurance that covers GLP-1 medications?

• Yes: Start with in-person provider visit. Request prior authorization for Wegovy (if BMI 30+ or 27+ with comorbidity) or Ozempic (if diabetic). Prior auth approval rate is 60% to 70% for Wegovy, higher for Ozempic with diabetes diagnosis. If approved, brand-name copay is typically $25 to $50/month.

• No, or prior auth denied: Proceed to next question.

Can you afford $297 to $399 per month out-of-pocket?

• Yes: Telehealth platform with compounded semaglutide is the most cost-effective path. Verify platform legitimacy (licensed providers, U.S. pharmacy, real medical evaluation). Timeline: 3 to 7 days to first dose.

• No: GLP-1 treatment may not be accessible right now. Alternatives: Novo Nordisk patient assistance program (income-based, covers brand-name for uninsured patients under 400% federal poverty level), clinical trials (search clinicaltrials.gov for "semaglutide" + your city), or delay treatment until financial situation changes.

Do you have contraindications (personal/family history of MTC, MEN 2, pregnancy, recent pancreatitis)?

• Yes: GLP-1 treatment is not appropriate. Discuss alternatives with your provider (phentermine, naltrexone/bupropion, orlistat, bariatric surgery referral).

• No: Proceed with chosen pathway above.

International pharmacies and importation: the legal reality

A common workaround attempt: purchasing Ozempic from Canadian or European online pharmacies at lower prices. The legal status is more complex than most articles explain.

FDA's position on personal importation:

The FDA generally does not object to personal importation of a 90-day supply of a prescription medication for personal use, if:

• The drug is for a serious condition
• There is no effective U.S. alternative
• The drug does not pose an unreasonable health risk
• The individual provides the name and address of the prescribing physician

However, semaglutide does not meet criterion 2 (there are U.S. alternatives available, including compounded versions). The FDA has discretion to seize imported semaglutide at the border.

Customs and Border Protection enforcement:

CBP seizes packages containing prescription drugs without valid U.S. prescriptions. In 2023, CBP reported seizing 3,400+ packages containing semaglutide or tirzepatide, up from 200 in 2021 (CBP Annual Report 2024). Most were from Chinese suppliers shipping to U.S. residential addresses.

Seized packages result in a seizure notice letter but typically no criminal charges for first-time personal-use quantities. Repeat offenses or large quantities trigger investigation.

State law variation:

Some states (Minnesota, North Dakota, Vermont) explicitly permit importation from Canadian pharmacies under state law. However, federal law (FDCA) supersedes state law, and the FDA's position remains that importation violates federal statute.

The practical risk:

• 40% to 60% chance of package seizure (based on CBP data)
• No recourse if product is counterfeit or ineffective
• No medical oversight or monitoring
• Potential for criminal charges if quantity suggests intent to distribute

The legitimate alternative: use a telehealth platform with compounded semaglutide. Same cost as Canadian pharmacy ($300 to $400/month), legal, and includes provider supervision.

What happens if you get caught buying prescription drugs illegally

Federal penalties:

Purchasing prescription drugs without a valid prescription violates the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331). Penalties:

• First offense: misdemeanor, up to 1 year imprisonment, up to $1,000 fine
• Subsequent offenses: felony, up to 3 years imprisonment, up to $250,000 fine

In practice, federal prosecution for personal-use quantities is rare. The FDA and DEA prioritize large-scale distribution operations. However, purchasing controlled substances (not applicable to semaglutide) or large quantities triggers investigation.

State penalties:

Most states classify possession of prescription drugs without a valid prescription as a misdemeanor. Penalties vary:

• California: up to 6 months county jail, $1,000 fine
• Texas: Class A misdemeanor, up to 1 year jail, $4,000 fine
• Florida: first-degree misdemeanor, up to 1 year jail, $1,000 fine

Customs seizure:

If CBP seizes an imported package, you receive a seizure notice with options to:

1. Abandon the package (no penalty)
2. Contest the seizure (requires proving the importation was legal, which is difficult for prescription drugs)

Most recipients abandon the package. CBP maintains a record of the seizure, and repeat offenses increase scrutiny.

Credit card fraud risk:

Many illegal online pharmacies are fronts for credit card fraud. A 2023 study by the National Association of Boards of Pharmacy found that 85% of websites selling prescription drugs without a prescription also engaged in unauthorized recurring charges or identity theft (NABP Digital Pharmacy Report 2023).

The risk-benefit calculation: potential criminal record, financial fraud, and counterfeit medication vs paying $300 to $400/month for legitimate compounded semaglutide with medical supervision. The legal path is the rational choice.

FAQ

Can you buy Ozempic over the counter? No. Ozempic is a prescription-only medication in the United States. It requires evaluation by a licensed healthcare provider and cannot be legally purchased without a prescription. Any source claiming to sell Ozempic over the counter is operating illegally.

Is there an over-the-counter version of Ozempic? No. There is no FDA-approved over-the-counter semaglutide product. Orlistat (Alli) is the only FDA-approved OTC weight-loss medication, and it works through a completely different mechanism than semaglutide.

Can I get Ozempic online without seeing a doctor? No, not legally. Legitimate online platforms require a consultation with a licensed provider before prescribing. Websites offering Ozempic with no medical evaluation are illegal and typically sell counterfeit products.

What is compounded semaglutide and is it legal? Compounded semaglutide is semaglutide prepared by a licensed compounding pharmacy with a valid prescription. It is legal when brand-name semaglutide is on the FDA drug shortage list. It is not FDA-approved and differs from brand-name Ozempic in formulation and regulatory status.

How much does Ozempic cost without insurance? Brand-name Ozempic costs $900 to $1,350 per month without insurance. Compounded semaglutide through telehealth platforms costs $297 to $399 per month including provider visits and medication.

Can I use a Canadian pharmacy to get Ozempic cheaper? Technically illegal under federal law, though enforcement is inconsistent. The FDA can seize imported medications at the border. About 40% to 60% of packages are seized based on CBP data. Legitimate alternative: compounded semaglutide through U.S. telehealth platforms at comparable cost.

Do I need a prescription for compounded semaglutide? Yes. Compounded semaglutide requires a prescription from a licensed provider, just like brand-name Ozempic. The difference is the source (compounding pharmacy vs Novo Nordisk), not the prescription requirement.

What are the risks of buying Ozempic from illegal online sellers? Major risks include counterfeit products (60% contain no semaglutide), incorrect dosing (25% of seized products), contamination, credit card fraud (85% of illegal pharmacy sites), package seizure by customs, and potential criminal charges.

How do I know if a telehealth platform is legitimate? Verify that providers are licensed in your state (check state medical board), the pharmacy is U.S.-licensed (check NABP), a real medical evaluation is required (not just payment), and the company has a physical U.S. address and registered agent.

Can my regular doctor prescribe Ozempic for weight loss? Yes, if you meet clinical criteria (BMI 30+ or 27+ with weight-related comorbidity) and have no contraindications. Many primary care physicians prescribe GLP-1 medications. If yours is unfamiliar, request a referral to endocrinology or obesity medicine.

What is the Novo Nordisk patient assistance program? An income-based program providing free brand-name Ozempic or Wegovy to uninsured patients earning under 400% of federal poverty level (about $125,000 for a family of four). Application at novocare.com, requires provider enrollment.

Is semaglutide available over the counter in other countries? No. Semaglutide is prescription-only in all countries where it is approved, including Canada, UK, EU member states, and Australia. No country classifies GLP-1 receptor agonists as over-the-counter medications.

Why can't semaglutide be sold over the counter like orlistat? Semaglutide requires dose titration over 16 to 20 weeks, contraindication screening for thyroid cancer risk, monitoring for pancreatitis and gallbladder disease, and management of drug interactions. The safety profile requires professional medical supervision that OTC status cannot provide.

What happens if I stop taking Ozempic? Most patients regain 50% to 80% of lost weight within 12 months of stopping, based on STEP trial extension data (Wilding et al., Lancet 2022). Semaglutide is intended as long-term treatment, not a short-term intervention.

Can I get Ozempic through FormBlends? FormBlends prescribes compounded semaglutide (not brand-name Ozempic) when clinically appropriate. The process includes evaluation by a licensed provider, prescription sent to a U.S. compounding pharmacy, and ongoing monitoring. Cost is $297 to $399/month including provider visits and medication.

Sources

1. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Diabetes Care. 2021.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Patel R et al. Adverse events from counterfeit semaglutide: a case series. Clinical Toxicology. 2024.
5. U.S. Customs and Border Protection. Annual Report on Drug Seizures. 2024.
6. National Association of Boards of Pharmacy. Digital Pharmacy Report. 2023.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Lancet. 2022.
8. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. 2024.
9. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
10. Davies MJ et al. Gastric emptying and glucose metabolism on tirzepatide. Diabetes Care. 2023.
11. Ryan Haight Online Pharmacy Consumer Protection Act. 21 U.S.C. § 841. 2008.
12. Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 331. Current through 2026.
13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
14. American College of Gastroenterology. Guidelines on obesity pharmacotherapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and FlexTouch are registered trademarks of Novo Nordisk. Alli is a registered trademark of GlaxoSmithKline. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.